BSE Pharma Sector Regulatory Filings — May 13, 2026
Across 17 filings from BSE Pharma constituents, FY26 results reveal muted revenue growth averaging ~2% YoY for GSK Pharma (up 2% to ₹3822 Cr) and Cipla (up 2.2% to ₹28,163 Cr), with Q4 showing QoQ declines (GSK -4%, Cipla -2.8% YoY/-7.6% QoQ). Profit trends diverge sharply: GSK up 12% YoY to ₹1036 Cr aided by ₹20.6 Cr exceptional credit and 2% lower expenses, while Cipla plunged 26.7% YoY to ₹3862 Cr due to ₹276 Cr exceptional loss and impairments. Capital allocation remains shareholder-friendly with GSK hiking final dividend to Rs.57/share (up from Rs.54 total FY25), Cipla at Rs.13/share, and Zydus proposing buyback on May 19 plus acquiring Assertio for $166M to bolster US oncology footprint (ROLEDON +13.6% YoY). Mixed sentiment dominates (9/17 filings), with neutral on earnings events; no insider trades noted but positive on Zydus M&A. Key catalysts cluster in May-June: earnings (Zydus/Sun May 19/22), dividend records (GSK May 29, Cipla June 5), AGMs (Cipla June 25, GSK June 30). Sector implies steady returns amid flat growth, watch for Q4 weakness signaling demand softness.